Clinical Day

The Clinical Day is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the University of Ottawa’s Office of Continuing Professional Development. Attendees may claim a maximum of 7 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™.

For information on the process to convert Royal College MOC credit to AMA credit go to www.ama-assn.org/education/cme

The European Union of Medical Specialists-European Accreditation Council for CME (UEMS-EACCME®) will convert the number of MOC Section 1 - Accredited Group Learning credit granted by a Royal College accredited CPD provider into ECMECs®, upon first request of a physician. This recognition is limited to live events held outside of the European Union as well as the jurisdictions of the non-European Union countries represented at the UEMS as members.

LEARNING OUTCOMES

• Attendees will be able to describe differences between alpha and beta radiopharmaceuticals with respect to physical characteristics of radiation and their biological effect.

• Attendees will be able to list clinical situations where alpha-labeled ligands are being applied for therapy of disease.

8:00 AM
Opening Remarks
Dr. Wim Oyen, Professor of Nuclear Medicine and Molecular Imaging & Team Leader in Translational Molecular Imaging, The Institute of Cancer Research and Dr. Lionel Zuckier, Professor of Medicine and Radiology, University of Ottawa & Director of Research, Division of Nuclear Medicine, The Ottawa Hospital

Session I. Alphas as a New Tool in the Clinical Armamentarium – Basic Concepts

8:15 AM
Targeted Radioimmunotherapy and Theranostics
Dr. Neeta Pandit-Taskar, Attending, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center & Clinical Director, Center for Radioimmunotargeted Imaging and Theranostics, Ludwig Center for Cancer Immunotherapy

8:45 AM
Development of Alpha Therapy, from Benchtop to Clinic
Prof. Alfred Morgenstern, Senior Researcher, European Commission, Joint Research Centre, Directorate of Nuclear Safety and Security

9:15 AM
The Clinical Case for Incorporating Dosimetry in Alpha-Emitter Therapy
Dr. George Sgouros, Professor of Radiology & Radiological Science, Johns Hopkins University, School of Medicine

9:45 AM – 10:15 AM
Networking Break – Visit exhibits and posters

Session II. Ra-223 Therapy as an Approved Modality for Treatment of Bony Metastases: From ALSYMPCA to Clinical Practice at The Ottawa Hospital

10:15 AM
A Radiation Oncology Perspective
Dr. Scott Morgan, Radiation Oncologist, The Ottawa Hospital & Assistant Professor, Division of Radiation Oncology, University of Ottawa

10:45 AM
A Nuclear Medicine Perspective
Dr. Eugene Leung, Division of Nuclear Medicine, The Ottawa Hospital

11:15 AM
A Radiation Safety Perspective
Mr. Jon Aro, Radiation Safety Officer, The Ottawa Hospital

11:45 AM – 1:00 PM
Lunch Break (on your own)

Session III. Regulatory Aspects of Alpha Therapy in Patients

Moderator: Dr. Patrick Causey

1:00 PM
Panel Discussion – A Canadian Perspective

Mr. Neil Babcock, Licensing Project Officer, Directorate of Nuclear Substance Regulation, Canadian Nuclear Safety Commission

Dr. Corinne Bensimon, Senior Reviewer, CMC, Radiopharmaceuticals and Gene Therapies Unit CERB, Health Canada

Mr. Patrick Ruddock, Manager, Regulatory Affairs, Centre for Probe Development and Commercialization

Mr. Paul Gustafson, Senior Corporate Regulatory Compliance and Enforcement Advisor, Regulatory Operations and Enforcement Branch, Health Canada
### Session IV. Emerging Vistas in Alpha Therapy

**1:45 PM**  
**PSMA and Soft-tissue Metastases**  
*Dr. Wim Oyen, Professor of Nuclear Medicine and Molecular Imaging & Team Leader in Translational Molecular Imaging, The Institute of Cancer Research*

**2:15 PM**  
**Targeted Alpha-Particle Therapy for Hematologic Malignancies**  
*Dr. Joseph G. Jurcic, Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology*

**2:45 PM**  
**Future Vistas in Alpha Therapy of Infectious Diseases**  
*Dr. Ekaterina Dadachova, Sylvia Fedoruk Centre for Nuclear Innovation Chair in Radiopharmacy and Professor, University of Saskatchewan*

**3:15 PM – 3:30 PM**  
Networking Break – Visit exhibits and posters

### Session V. Clinical Abstract Presentations

**Moderator: Dr. Ran Klein**

**3:30 PM**  
**Alpha DaRT: Revolutionary Alpha-Emitters Brachytherapy**  
*Dr. Lior Arazi, Nuclear Engineering Unit, Faculty of Engineering Sciences, Ben-Gurion University*

**3:45 PM**  
**Ac-225-PSMA-617 in Chemotherapy-naive Patients with Advanced Prostate Cancer**  
*Prof. Mike Sathekge, University of Pretoria*

**4:00 PM**  
**Safety and Efficacy of Ac-225-PSMA-617 in mCRPC after Failure of Lu-177-PSMA**  
*Dr. Benedikt Feuerecker, Technische Universität München, Department of Nuclear Medicine*

**4:15 PM**  
**Safety and Therapeutic Efficacy of Ac-225-DOTA-Substance P for Therapy of Brain Tumors**  
*Dr. Frank Bruchertseifer, European Commission, JRC-Karlsruhe*

**4:30 PM**  
**Improved Tumor Control and Absence of Late Neurotoxicity using Alpha (213Bi) as Compared to Beta (90Y) Labelled-DOTA-Substance P for the Treatment of Low Grade Gliomas**  
*Prof. Adrian Merlo, University of Basel*

**4:45 PM**  
**Targeted Alpha-emitter Therapy of Neuroendocrine Tumors using 212Pb-octreotate (AlphaMedix TM)**  
*Dr. Ebrahim S. Delpassand, RadioMedix Inc.*

**5:00 PM**  
**Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose Estimations**  
*Dr. Per Albertsson, Department of Oncology, Sahlgrenska University Hospital*

### Session VI. Conference Summation and Overview

**5:15 PM**  
**Where Do We See Alpha Emitters in Clinical Practice. A Radiation Oncology Perspective**  
*Dr. Joe O’Sullivan, Prostate Cancer Oncologist, Northern Ireland Cancer Centre & Professor of Radiation Oncology, Centre for Cancer Research and Cell Biology, Queen’s University Belfast*

**5:45 PM**  
**Alpha Therapeutics from a Prostate Oncologic Standpoint**  
*Dr. Michael Morris, Section Head, Prostate Cancer, Memorial Sloan Kettering Cancer Center*

**6:15 PM**  
**Closing Remarks**  
*Dr. Wim Oyen, Professor of Nuclear Medicine and Molecular Imaging & Team Leader in Translational Molecular Imaging, The Institute of Cancer Research and Dr. Lionel Zuckier, Professor of Medicine and Radiology, University of Ottawa & Director of Research, Division of Nuclear Medicine, The Ottawa Hospital*